Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals, Inc. SVP, Global Controller Jolanda Howe exercised 16,112 employee stock options on October 16, 2026, acquiring 16,112 common shares at an exercise price of $19.24 per share. The option was fully vested. After the transaction, the option row lists 8,888 options, and Howe’s reported common-stock holdings were 16,728 shares.
Mirum Pharmaceuticals, Inc. (MIRM) Chief Medical Officer Robert Paul Myers received a grant on October 9, 2026, of employee stock options covering 40,000 common shares with an $86.01 exercise price and 25,000 restricted stock units. The options vest in installments beginning one year after September 21, 2026; the RSUs vest over three years.
Mirum Pharmaceuticals, Inc. (MIRM) announced topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases. The study enrolled 52 patients and met its primary endpoint, with statistical significance across all five prespecified secondary endpoints. In the pediatric primary analysis, the mean ItchRO(Obs) score improved by 1.81 points with maralixibat versus 0.83 points with placebo during Weeks 13–20, a 0.98-point treatment difference (p=0.0004). Serum bile acids declined 70.1% with maralixibat versus 3.5% with placebo, with a 69.0% treatment effect (p<0.0001).
Safety findings were consistent with prior clinical experience, and no new safety signals were observed. Serious treatment-emergent adverse events occurred in five participants in each group; diarrhea was reported in 16 participants (64.0%) receiving maralixibat and three (11.1%) receiving placebo. Mirum plans to submit a supplemental New Drug Application in the United States in the first half of 2027 based on these results.
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised fully vested options on October 6, 2026, to acquire 5,305 common shares at an exercise price of $19.19 per share and 6,892 common shares at $15.87 per share. The reported transactions dispose of the options and acquire the underlying shares. A separate holding entry reports 187,500 common shares held indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals, Inc. (MIRM) announced FDA approval of Atebrioz (zilurgisertib) to reduce the volume of total new heterotopic ossification in adults and children aged 12 years and older with FOP. The recommended dose is 100 mg orally once daily. In the 24-week PROGRESS Cohort 1 study, mean total new HO lesion volume decreased by 3.2 cm³ with zilurgisertib, versus an increase of 24.6 cm³ with placebo; treatment effects were maintained through Week 48. Developed by Incyte and licensed to Mirum, Atebrioz is expected to be commercially available in the U.S. in October through Mirum Access Plus, which offers access support and financial assistance to eligible patients.
Separately, brelovitug met the AZURE-1 Phase 3 primary endpoint at Week 24: 56% on 300 mg weekly and 45% on 900 mg every four weeks achieved virologic response plus ALT normalization, versus 0% with delayed treatment. Mirum reported deeper viral suppression and increased ALT normalization in 48-week Phase 2b data. The company expects AZURE-4 topline results in the fourth quarter of 2026, a BLA submission in the first half of 2027 and a potential U.S. launch in the fourth quarter of 2027. It estimates annual revenue potential of more than $1 billion for brelovitug in HDV and greater than $200 million for Atebrioz in FOP; zilurgisertib’s EU application is under review.
Mirum Pharmaceuticals, Inc. (MIRM) lists Chief Medical Officer Robert Paul Myers as directly holding 55 shares of common stock in an ownership entry dated September 21, 2026. The entry reports a holding rather than a stated purchase or sale.
Mirum Pharmaceuticals, Inc. (MIRM) has a planned sale of up to 9,943 shares of common stock under Rule 144 for the account of officer Eric Bjerkholt, through Morgan Stanley Smith Barney LLC. The notice describes the sale as a sell-to-cover transaction for taxes on recently vested stock unit awards.
The filing also reports prior sales by Bjerkholt in the last three months totaling 11,001 shares of Mirum common stock.
Mirum Pharmaceuticals, Inc. (MIRM) reported that its Chief Financial Officer, Eric Bjerkholt, had Restricted Stock Units (RSUs) covering 18,333 shares of common stock vest and convert into common shares on September 11, 2026, at no cash exercise price, canceling the corresponding RSU derivative position.
On September 14, 2026, he then sold 9,943 shares of Mirum common stock in a direct transaction at a price of $98.37 per share, with the company disclosing that the sale was to cover tax withholding obligations related to the RSU vesting. No Rule 10b5-1 trading plan is reported for these transactions.
Mirum Pharmaceuticals, Inc. (MIRM) reports a leadership transition in its medical organization. The board appointed Rob Myers, M.D. to succeed Joanne Quan, M.D. as Chief Medical Officer, effective when Dr. Myers begins employment, which is expected on September 21, 2026. Dr. Quan ceased serving as Chief Medical Officer on September 2, 2026, and her employment termination is expected on October 19, 2026, the defined “Separation Date.”
Mirum expects to enter into a Separation Agreement with Dr. Quan providing severance benefits under its Amended and Restated Severance Benefit Plan, subject to its terms. The compensation committee also approved a 12‑month post‑termination option exercise window for Dr. Quan’s vested options and payment of her 2026 annual target bonus at 100% achievement on the Separation Date, contingent on customary conditions.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Jolanda Howe, its Senior Vice President and Global Controller, sold 658 shares of common stock on September 2, 2026 in a sale described as occurring in the open market or a private transaction at $100.00 per share.
After this sale, Howe held 616 shares of Mirum common stock directly. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted by Howe on March 18, 2026, indicating it was pre-arranged.